Screener / SEC EDGAR /CIK 0001651308 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq, OTC Health care · Pharmaceuticals

BeOne Medicines Ltd. ONC

We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. 10-K, Item 1

Employees
12,000
Headquarters
Basel
CEO
John Oyler
Next results
around Feb 25, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $5.3B through the costs to a net profit of $286.9M · income statement of the 10-K

8% operating margin
Revenue to Gross profit: $4.7BRevenue to Cost of revenue: $668.5MGross profit to Operating profit: $447.1MGross profit to Operating expenses: $4.2BOperating profit to Net profit: $286.9MOperating profit to Tax & other: $160.2MOperating expenses to R&D: $2.1BOperating expenses to SG&A: $2.1B Revenue: $5.3B REVENUE $5.3B +40% Y/Y Gross profit: $4.7B · 87% margin GROSS PROFIT $4.7B 87% margin · +45% Y/Y Cost of revenue: $668.5M · 13% of revenue COST OF REVENUE $668.5M 13% of revenue Operating profit: $447.1M · 8% margin OPERATING PROFIT $447.1M 8% margin Operating expenses: $4.2B · 79% of revenue OPERATING EXPENSES $4.2B 79% of revenue Net profit: $286.9M · 5% margin NET PROFIT $286.9M 5% margin Tax & other: $160.2M · 3% of revenue TAX & OTHER $160.2M 3% of revenue R&D: $2.1B · 40% of revenue R&D $2.1B 40% of revenue SG&A: $2.1B · 39% of revenue SG&A $2.1B 39% of revenue
Gross profit $4.7B 87% margin · +45% Y/Y
Operating profit $447.1M 8% margin
Net profit $286.9M 5% margin
The full income statement, year by year

ONC among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 40.2%, above 88% of 154 peers (their median 10.4%) REVENUE GROWTH 40.2% · above 88% Gross margin: 89.4%, above 94% of 107 peers (their median 63.4%) GROSS MARGIN 89.4% · above 94% Operating margin: 17.8%, above 72% of 138 peers (their median 9.8%) OPERATING MARGIN 17.8% · above 72% Net margin: 13.9%, above 71% of 153 peers (their median 6.7%) NET MARGIN 13.9% · above 71% FCF margin: 21.9%, above 83% of 144 peers (their median 9.9%) FCF MARGIN 21.9% · above 83% Return on capital: 4.6%, above 16% of 89 peers (their median 9.2%) RETURN ON CAPITAL 4.6% · above 16%
ONC Peer median Below the median

What changed

32 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 27, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Gross-to-Net U.S. Accruals for Sales Chargebacks and Third-Party Managed Rebates (“At December 31, 2025, the Company recorded $79.1 million of contra AR accruals and $398.5 million of accrued rebates, returns and other deductions. As discussed in Note 2 to the consolidated financial statements under the caption “Revenue Recognition,” the Company recognizes revenue when the transfe”). No longer listed: Product Revenue, Net
  • Receivables +27.9% ($676.3M to $865.1M) vs revenue +40.2% ($3.8B to $5.3B), -12.3 pts apart
9 more checks with nothing to note
  • Cash from operations $1.1B vs net income $286.9M (FY ending Dec 31, 2025)
  • Inventory +22.9% ($495.0M to $608.2M) vs revenue +40.2% ($3.8B to $5.3B), -17.4 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

32 paragraphs in Risk Factors that were not in the 10-K filed Feb 27, 2025. Quoted as filed.

All 32 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    In April 2025, the Trump administration published Executive Order 14273 (90 Fed. Reg. 16441), “Lowering Drug Prices by Once Again Putting Americans First,” which generally directs the U.S. Department of Health and Human Services (“HHS”) to take steps to reduce drug prices. In May 2025, the administration published Executive Order 14297…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Furthermore, on April 1, 2025, the Bureau of Industry and Security of the U.S. Department of Commerce (“BIS”) initiated an investigation into whether imports of pharmaceutical products present a risk to the national security of the U.S. This investigation could result in BIS recommending additional tariffs on imports of pharmaceutical…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and we cannot predict with any certainty the success of any clinical trial or whether or when we might complete a given clinical trial. We may also experience…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 27, 2025 10-K, ITEM 1A
    Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business. On May 12, 2025, President Trump issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S.…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$1.4B$2.5B$3.8B$5.3B
Net income−$2.0B−$881.7M−$644.8M$286.9M
Operating cash flow−$1.5B−$1.2B−$140.6M$1.1B
Free cash flow−$1.8B−$1.7B−$633.3M$941.7M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$5.3B ▲ 40.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

BeOne Medicines Ltd., Basel · from the 10-K filed Feb 26, 2026

We are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.

Headquarters
Basel
Reports in
USD
Listed on
Nasdaq, OTC
Fiscal year ends
December 31
Last results
Nov 5, 2026

Employees, at the top of the page: "As of February 13, 2026, we had nearly 12,000 full-time employees worldwide, across six continents, with approximately 1,900 employees in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 27, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ONC/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.